Wegovy HD 7.2mg: What This Means for Men's Weight Loss
The FDA approved Wegovy HD today — semaglutide at 7.2mg, delivering 20.7% average weight loss. Here's why the higher dose is particularly relevant for men.
Dose: 7.2mg once-weekly injection (3x standard Wegovy)
Weight loss: 20.7% mean at 72 weeks (STEP UP trial)
Key stat: 1 in 3 participants lost 25% or more of body weight
Approval: May 13, 2026 — accelerated 54-day review
Why Higher Doses Matter for Men
Men typically have higher lean body mass and greater blood volume than women, which affects how semaglutide distributes through the body. Some research suggests men may need higher doses to achieve equivalent appetite suppression and metabolic effects. Wegovy HD at 7.2mg directly addresses this pharmacokinetic reality.
For a 230-pound man, 20.7% weight loss translates to roughly 48 pounds. And at the 25% threshold (achieved by one-third of participants), that's nearly 58 pounds — enough to fundamentally change cardiovascular risk, testosterone levels, and physical performance.
STEP UP Trial Numbers
| Metric | Wegovy HD (7.2mg) | Standard (2.4mg) |
|---|---|---|
| Mean weight loss | 20.7% | ~15% |
| Achieved ≥25% loss | ~33% | ~12% |
| Cardiovascular benefit | Yes (SELECT data) | Yes |
The Testosterone Connection
Greater weight loss typically means greater testosterone recovery for obese men. The aromatase enzyme in fat tissue converts testosterone to estrogen — less fat means less conversion. Men achieving 20%+ weight loss on semaglutide have reported testosterone increases of 100-200+ ng/dL, potentially eliminating the need for TRT in cases where obesity is the primary driver of low T.
SkinnyRx · from $149/mo
Explore GLP-1 Options →Compounded medications are not FDA-approved. Paid link
Safety at This Dose
Side effects remain consistent with lower doses — nausea, diarrhea, vomiting during titration. One new finding: altered skin sensation (sensitivity, burning) reported more frequently at 7.2mg. This typically resolves with dose adjustment. The boxed warning about thyroid C-cell tumors applies at all semaglutide doses.
Current Options While Wegovy HD Launches
Wegovy HD is expected in pharmacies by mid-2026. In the meantime, current GLP-1 options deliver strong results:
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
from $147/mo
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
The Bottom Line
Wegovy HD brings semaglutide into tirzepatide-level efficacy for the first time. For men who plateaued on standard doses or need aggressive intervention, this changes the calculus. Current compounded and brand-name options remain solid choices while the HD formulation rolls out.
Sources
- FDA approval, Wegovy HD (semaglutide 7.2mg), May 13, 2026
- STEP UP phase 3 trial (NCT05646706)
- Corona G, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism, JCEM 2013